Advertisement
U.S. Markets closed
S&P Futures
5,887.25 -5.25 (-0.09%) Dow Futures
43,043.00 -126.00 (-0.29%) Nasdaq Futures
20,519.25 -22.75 (-0.11%) Russell 2000 Futures
2,246.10 -0.10 (-0.00%) Crude Oil
72.24 +0.15 (+0.21%) Gold
2,760.30 +0.50 (+0.02%)
Editas Medicine, Inc. (EDIT)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EDT
After hours:
| Previous Close | 3.7600 |
| Open | 3.7400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 3.2300 - 3.7500 |
| 52 Week Range | 2.9100 - 11.6900 |
| Volume | |
| Avg. Volume | 1,813,412 |
| Market Cap | 271.347M |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.3300 |
| Earnings Date | Nov 01, 2024 - Nov 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.47 |
Pharmaceutical TechnologyEditas and Genevant team up to develop gene editing therapies
Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.
ZacksEDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
Editas signs a license agreement with Genevant Sciences to develop novel mRNA-LNP gene editing therapeutics. Shares rise in after-hours trading.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.